Shanghai Kaibao Pharmaceutical Financial Flexibility Index
Shanghai Kaibao Pharmaceutical financial flexibility index. Shanghai Kaibao Pharmaceutical (300039) has a Financial Flexibility Index of 0.47x as of September 2025. Free cash flow of CN¥194.35 Million (operating CF CN¥190.98 Million minus capex CN¥3.37 Million) represents 0% of total liabilities (CN¥412.55 Million). See Shanghai Kaibao Pharmaceutical free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Shanghai Kaibao Pharmaceutical (2006–2025)
Financial flexibility index of Shanghai Kaibao Pharmaceutical from 2006 to 2025. Historical Financial Flexibility Index trend for Shanghai Kaibao Pharmaceutical across 20 annual periods. Check Shanghai Kaibao Pharmaceutical earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Shanghai Kaibao Pharmaceutical Financial Flexibility Index by Year (2006–2025)
Shanghai Kaibao Pharmaceutical financial flexibility index by year from 2006 to 2025. Year-by-year free cash flow to debt coverage for Shanghai Kaibao Pharmaceutical. For the full cash flow conversion analysis, see 300039 cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.72x | CN¥257.78 Million | CN¥230.74 Million | CN¥359.64 Million | ▼ -29.0% |
| 2024 | 1.01x | CN¥419.47 Million | CN¥278.95 Million | CN¥415.45 Million | ▲ +34.1% |
| 2023 | 0.75x | CN¥411.74 Million | CN¥382.66 Million | CN¥546.82 Million | ▼ -8.1% |
| 2022 | 0.82x | CN¥408.04 Million | CN¥376.42 Million | CN¥498.24 Million | ▲ +51.0% |
| 2021 | 0.54x | CN¥168.63 Million | CN¥126.08 Million | CN¥310.90 Million | ▼ -38.7% |
| 2020 | 0.89x | CN¥264.59 Million | CN¥250.65 Million | CN¥298.96 Million | ▼ -30.9% |
| 2019 | 1.28x | CN¥349.54 Million | CN¥334.09 Million | CN¥273.01 Million | ▲ +16.4% |
| 2018 | 1.10x | CN¥288.43 Million | CN¥262.36 Million | CN¥262.26 Million | ▲ +17.2% |
| 2017 | 0.94x | CN¥295.00 Million | CN¥245.76 Million | CN¥314.26 Million | ▼ -10.1% |
| 2016 | 1.04x | CN¥341.91 Million | CN¥314.88 Million | CN¥327.61 Million | ▲ +16.4% |
| 2015 | 0.90x | CN¥377.48 Million | CN¥327.08 Million | CN¥421.16 Million | ▼ -40.6% |
| 2014 | 1.51x | CN¥351.12 Million | CN¥282.38 Million | CN¥232.72 Million | ▼ -36.0% |
| 2013 | 2.36x | CN¥388.52 Million | CN¥270.23 Million | CN¥164.72 Million | ▲ +13.6% |
| 2012 | 2.08x | CN¥295.53 Million | CN¥243.32 Million | CN¥142.29 Million | ▲ +46.6% |
| 2011 | 1.42x | CN¥167.16 Million | CN¥98.31 Million | CN¥117.97 Million | ▲ +167.0% |
| 2010 | 0.53x | CN¥70.80 Million | CN¥19.79 Million | CN¥133.39 Million | ▼ -40.8% |
| 2009 | 0.90x | CN¥178.44 Million | CN¥52.74 Million | CN¥199.20 Million | ▲ +207.6% |
| 2008 | 0.29x | CN¥29.98 Million | CN¥18.70 Million | CN¥102.95 Million | ▼ -11.6% |
| 2007 | 0.33x | CN¥27.89 Million | CN¥23.27 Million | CN¥84.64 Million | ▼ -24.7% |
| 2006 | 0.44x | CN¥31.43 Million | CN¥19.70 Million | CN¥71.80 Million | — |